At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 4,766 enrolled
Drug / intervention
Interleukin 28B testingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes With Patient Demographics and Disease Characteristics in Patients With Chronic Hepatitis C
In Brief
A Phase 4 clinical trial evaluating Interleukin 28B testing for Hepatitis C, Chronic. Completed, enrolled 4,766 participants across 210 sites in 31 countries.
Detailed Summary
This multicenter study will evaluate the correlation of interleukin 28B (IL28B) genotypes with disease characteristics and demographics in treatment-naïve and treatment-experienced chronic hepatitis C patients, including patients with HIV co-infection. There will be a single study visit for testing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesArgentina, Belgium, Chile, Egypt, Estonia, France, Germany, Greece, Italy, Kuwait, Latvia, Lebanon, Lithuania, Mexico, North Macedonia, Oman, Pakistan, Peru, Portugal, Qatar, Romania, Serbia, Slovakia, Sweden, Switzerland, Syria, Taiwan, Turkey (Türkiye), United Arab Emirates, United States, Venezuela
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2012
Primary CompletionOct 2013
TodayJul 2026
First PostedAug 30, 2012
Enrollment StartAug 1, 2011
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.8 years ago
Interventions
Interleukin 28B testingother
Blood sampling for ILB28 genotyping